Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KELLEY WILSON

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1932398757
CMS profile
224261
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$717.46

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $661.54 2
Food and Beverage $55.92 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $661.54 2
Merck Sharp & Dohme LLC $55.92 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KELLEY WILSON

NPI 1932398757 · CMS profile ID 224261

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932398757?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932398757?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). KELLEY WILSON, NPI 1932398757, CMS profile ID 224261. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932398757?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
KELLEY WILSON, NPI 1932398757, CMS profile ID 224261, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1932398757?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $717.46 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $55.9212/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238330943 CMS
Eli Lilly and Company $364.9010/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186706789 CMS
Eli Lilly and Company $296.6410/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186713263 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,773.33 11
PY2020 $65.09 3
PY2021 $268.69 10
PY2022 $389.28 8
PY2023 $1,820.04 73
PY2024 $683.61 29
PY2025 $717.46 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,698,890.20 111
PY2024 Principal investigator $3,248,583.50 103
PY2023 Recipient $1,039.86 1
PY2023 Principal investigator $1,084,081.62 189
PY2022 Recipient $1,428.00 1
PY2022 Principal investigator $532,395.28 190
PY2021 Recipient $1,678.03 1
PY2021 Principal investigator $1,711,588.07 233
PY2020 Principal investigator $1,081,919.61 115
PY2019 Principal investigator $698,002.09 160

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

103 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $273,799.00 12/23/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079019340
Principal investigator 1 Janssen Research & Development, LLC $755.00 12/23/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079019342
Principal investigator 1 Janssen Research & Development, LLC $11,560.00 12/23/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079019346
Principal investigator 1 Janssen Research & Development, LLC $755.00 12/23/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079019352
Principal investigator 1 Janssen Research & Development, LLC $755.00 12/23/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079019354
Principal investigator 1 Janssen Research & Development, LLC $134.00 12/23/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079019358
Principal investigator 1 Janssen Research & Development, LLC $1,200.00 12/23/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079019360
Principal investigator 1 Janssen Research & Development, LLC $244,723.00 12/20/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079019344
Principal investigator 1 Janssen Research & Development, LLC $443,409.00 12/20/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079019348
Principal investigator 1 Janssen Research & Development, LLC $22,310.00 12/20/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079019350
Principal investigator 1 H. Lundbeck A S $7,887.00 12/10/2024 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1145887976
Principal investigator 1 Janssen Research & Development, LLC $18,522.00 12/06/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1079019336
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $81,680.95 11/08/2024 Non-covered Recipient Entity
K2 Medical Research
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1123477955
Principal investigator 1 Janssen Research & Development, LLC $14,000.00 11/04/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1079019338
Principal investigator 1 Janssen Research & Development, LLC $21,512.00 10/14/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1079019356
Principal investigator 1 H. Lundbeck A S $666.67 10/09/2024 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1145887426
Principal investigator 1 H. Lundbeck A S $4,000.00 10/09/2024 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1145887430
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,920.00 09/25/2024 Non-covered Recipient Entity
Advarra Inc.
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (TargetTau-1) No dispute reported 06/30/2026 1123475688
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $12,750.00 09/11/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment No dispute reported 06/30/2026 1143129951
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 08/30/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431210
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,762.89 08/27/2024 Non-covered Recipient Entity
K2 Medical Research
Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer s Disease (TargetT No dispute reported 06/30/2026 1123477957
Principal investigator 1 Roche Diagnostics Operations, Inc. $12,684.35 08/08/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125624321
Principal investigator 1 Sumitomo Pharma America, Inc. $1,717.00 08/05/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431140
Principal investigator 1 Sumitomo Pharma America, Inc. $105.00 08/05/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431150
Principal investigator 1 Sumitomo Pharma America, Inc. $179.00 08/05/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431178
Principal investigator 1 Sumitomo Pharma America, Inc. $15.84 08/05/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431222
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 07/31/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431208
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 06/28/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431206
Principal investigator 1 Roche Diagnostics Operations, Inc. $2,625.00 06/25/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125623550
Principal investigator 1 Sumitomo Pharma America, Inc. $60,446.60 06/24/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431176
Principal investigator 1 Sumitomo Pharma America, Inc. $15.84 06/24/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431220
Principal investigator 1 Incyte Corporation $440.00 06/04/2024 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1134705369
Principal investigator 1 Sumitomo Pharma America, Inc. $55.28 06/04/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431192
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 05/31/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431204
Principal investigator 1 Roche Diagnostics Operations, Inc. $45,423.30 05/28/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125623411
Principal investigator 1 Roche Diagnostics Operations, Inc. $30,682.80 05/28/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125623441
Principal investigator 1 Sumitomo Pharma America, Inc. $49,057.05 05/17/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431152
Principal investigator 1 Roche Diagnostics Operations, Inc. $68,134.95 05/14/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125623045
Principal investigator 1 Roche Diagnostics Operations, Inc. $40,910.40 05/07/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125623559
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 04/30/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431202
Principal investigator 1 Eli Lilly and Company $11.93 04/22/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH - TAMPA
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1137360721
Principal investigator 1 Roche Diagnostics Operations, Inc. $271,176.00 04/18/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125620432
Principal investigator 1 Roche Diagnostics Operations, Inc. $2,800.00 04/18/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125622793
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $227,291.38 04/17/2024 Non-covered Recipient Entity
K2 Medical Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease No dispute reported 06/30/2026 1123477949
Principal investigator 1 Sumitomo Pharma America, Inc. $50,141.00 04/15/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431154
Principal investigator 1 Incyte Corporation $2,146.55 04/11/2024 Non-covered Recipient Entity
OLYMPIAN CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1134705367
Principal investigator 1 Roche Diagnostics Operations, Inc. $126.00 04/09/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125622902
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $176,978.60 04/05/2024 Non-covered Recipient Entity
K2 Medical Research
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1123477951
Principal investigator 1 Roche Diagnostics Operations, Inc. $502.40 04/04/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125622849
Principal investigator 1 Sumitomo Pharma America, Inc. $105.00 04/03/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431148
Principal investigator 1 Sumitomo Pharma America, Inc. $1,603.18 04/03/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431162
Principal investigator 1 Roche Diagnostics Operations, Inc. $61,876.00 04/02/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125619833
Principal investigator 1 Roche Diagnostics Operations, Inc. $19,490.50 04/02/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125619961
Principal investigator 1 Roche Diagnostics Operations, Inc. $20,455.20 04/02/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125620118
Principal investigator 1 Roche Diagnostics Operations, Inc. $249,974.90 04/02/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125620200
Principal investigator 1 Roche Diagnostics Operations, Inc. $11,061.80 04/02/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125620394
Principal investigator 1 Roche Diagnostics Operations, Inc. $30,282.20 04/02/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125620495
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 03/29/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431200
Principal investigator 1 Roche Diagnostics Operations, Inc. $2,921.46 03/26/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125620989
Principal investigator 1 Sumitomo Pharma America, Inc. $385.00 03/26/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431138
Principal investigator 1 Sumitomo Pharma America, Inc. $2,240.00 03/26/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431156
Principal investigator 1 Roche Diagnostics Operations, Inc. $2,520.00 03/21/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125619931
Principal investigator 1 Roche Diagnostics Operations, Inc. $2,009.60 03/21/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125620605
Principal investigator 1 Roche Diagnostics Operations, Inc. $378.00 03/21/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125620681
Principal investigator 1 Roche Diagnostics Operations, Inc. $1,131.90 03/21/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125620685
Principal investigator 1 Roche Diagnostics Operations, Inc. $565.95 03/21/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125620896
Principal investigator 1 Sumitomo Pharma America, Inc. $36,285.25 03/15/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431174
Principal investigator 1 Sumitomo Pharma America, Inc. $105.00 03/06/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431146
Principal investigator 1 Sumitomo Pharma America, Inc. $69.10 03/05/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431190
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 02/29/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431198
Principal investigator 1 Sumitomo Pharma America, Inc. $84.00 02/23/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431136
Principal investigator 1 Sumitomo Pharma America, Inc. $210.00 02/23/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431144
Principal investigator 1 Sumitomo Pharma America, Inc. $105.00 02/23/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431164
Principal investigator 1 Sumitomo Pharma America, Inc. $799.00 02/23/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431172
Principal investigator 1 Sumitomo Pharma America, Inc. $79.18 02/21/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431218
Principal investigator 1 Sumitomo Pharma America, Inc. $210.00 02/14/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431142
Principal investigator 1 Sumitomo Pharma America, Inc. $12,941.85 02/14/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431168
Principal investigator 1 Sumitomo Pharma America, Inc. $85.00 02/14/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431170
Principal investigator 1 Roche Diagnostics Operations, Inc. $1,764.00 02/06/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125619909
Principal investigator 1 Sumitomo Pharma America, Inc. $25.00 02/04/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431212
Principal investigator 1 Sumitomo Pharma America, Inc. $15.84 02/04/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431216
Principal investigator 1 Roche Diagnostics Operations, Inc. $4,050.00 02/01/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125620436
Principal investigator 1 Sumitomo Pharma America, Inc. $185.35 02/01/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431214
Principal investigator 1 Sumitomo Pharma America, Inc. $70.00 01/31/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431196
Principal investigator 1 Roche Diagnostics Operations, Inc. $27,844.20 01/25/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125619936
Principal investigator 1 Roche Diagnostics Operations, Inc. $8,988.65 01/25/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125620101
Principal investigator 1 Roche Diagnostics Operations, Inc. $19,249.15 01/25/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125620208
Principal investigator 1 Sumitomo Pharma America, Inc. $63,127.50 01/19/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431166
Principal investigator 1 Sumitomo Pharma America, Inc. $1,483.99 01/12/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431158
Principal investigator 1 Sumitomo Pharma America, Inc. $3,046.88 01/12/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH TAMPA LLC
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431160
Principal investigator 1 Roche Diagnostics Operations, Inc. $7,875.00 01/11/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125619905
Principal investigator 1 Roche Diagnostics Operations, Inc. $525.00 01/11/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125620007
Principal investigator 1 Roche Diagnostics Operations, Inc. $399.40 01/11/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
RD006263 No dispute reported 06/30/2026 1125620148
Principal investigator 1 Eli Lilly and Company $1,151.89 01/09/2024 Non-covered Recipient Entity
ACADEMIC ALLIANCE IN DERMATOLOGY
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137350951
Principal investigator 1 PFIZER INC. $1,692.90 01/06/2024 Non-covered Recipient Entity
Academic Alliance in Dermatology dba Olympian Clinical Research
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1131035972
Principal investigator 1 Sumitomo Pharma America, Inc. $71.26 01/04/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431180
Principal investigator 1 Sumitomo Pharma America, Inc. $71.26 01/04/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431182
Principal investigator 1 Sumitomo Pharma America, Inc. $82.92 01/04/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431184
Principal investigator 1 Sumitomo Pharma America, Inc. $96.74 01/04/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431186
Principal investigator 1 Sumitomo Pharma America, Inc. $110.56 01/04/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431188
Principal investigator 1 Sumitomo Pharma America, Inc. $23.16 01/04/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder No dispute reported 06/30/2026 1148431194
Principal investigator 1 Eli Lilly and Company $35,176.00 01/02/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137361325
Principal investigator 1 Eli Lilly and Company $403,225.00 01/02/2024 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1137362211